A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein

Nuclear Medicine and Biology

Volumn 25, Issue 3, 1998, Pages 225-232

  Rao, Vallabhaneni V ^a   Herman, Lee W ^b   Kronauge, James F ^b   Piwnica Worms, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anticancer drugs; Membrane transport; Multidrug resistance; Organotechnetium complex; P glycoprotein

Indexed keywords

3,4,5 TRIMETHOXY PHENYL ISONITRILE TECHNETIUM TC 99M; GLYCOPROTEIN P; ISONITRILE DERIVATIVE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

EID: 0032054488     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00204-7     Document Type: Article

References (56)

1. 1. Abrams M. A., Davison A., Jones A. G., Costello C. E. and Pang H. (1983) Synthesis and characterization hexakis(alkyl isocyanide) and hexakis(arylisocyanide) complexes of technetium(I). Inorg. Chem. 22, 2798-2800.
2. 2. Akiyama S., Cornwell M. M., Kuwano M., Pastan I. and Gottesman M. M. (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol. Pharmacol. 33, 144-147.
3. 3. Ambudkar S. V., Ramachandra M., Cardarelli C. O., Pastan I. and Gottesman M. M. (1996) Modulation of human P-glycoprotein ATPase activity by interaction between overlapping substrate-binding sites. Proc. Am. Assoc. Cancer Res. 37, 325.
4. 4. Baldini N., Scotlandi K., Barbanti-Brodano G., Manara M., Maurici D., Bacci G., Bertoni F., Picci P., Sottili S., Campanacci M. and Serra M. (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N. Engl. J. Med. 333, 1380-1385.
5. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Commun. 16, 253-257.
6. 6. Bosch I., Crankshaw C., Piwnica-Worms D. and Croop J. (1997) Characterization of functional assays of P-glycoprotein transport activity. Leukemia 11, 1131-1137.
7. 7. Bosch I., Dunussi-Joannopoulos K., Wu R.-L., Furlong S. and Croop J. (1997) Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein. Biochemistry 36, 5685-5694.
8. 8. Callaghan R. and Higgins C. (1995) Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br. J. Cancer 71, 294-299.
9. 9. Cano-Gauci D. F. and Riordan J. R. (1987) Action of calcium antagonists on multidrug resistant cells: Specific cytotoxicity independent of increased cancer drug accumulation. Biochem. Pharmacol. 36, 2115-2123.
10. 10. Chiu M. L., Kronauge J. F. and Piwnica-Worms D. (1990) Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured mouse fibroblasts. J. Nucl. Med. 31, 1646-1653.
11. 11. Crankshaw C., Rao V. V. and Piwnica-Worms D. (1996) Modulation of MDR1 P-glycoprotein-mediated transport of Tc-99m-SESTAMIBI by GF120918 (GG918). Proc. Am. Assoc. Cancer Res. 37, 333.
12. 12. Dalton W. S., Grogan T. M., Meltzer P. S., Scheper J. J., Durie B. G., Taylor C. W., Miller T. P. and Salmon S. E. (1989) Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J. Clin. Oncol. 7, 415-424.
13. 13. Dantzig A., Shepard R., Cao J., Law K., Ehlhardt W., Baughman T., Bumol T. and Starling J. (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56, 4171-4179.
14. 14. Ford J. M. and Hait W. N. (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
15. 15. Gaveriaux C., Boesch D. and Jachez B. (1991) PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J. Cell. Pharmacol. 2, 225-234.
16. 16. Gerlach J. H., Kartner N., Bell D. R. and Ling V. (1986) Multidrug resistance. Cancer Surv. 5, 25-46.
17. 17. Glantz S. A. (1987) Primer of Biostatistics, 2nd ed. McGraw-Hill, New York.
18. 18. Goldstein L. J., Galski H., Fojo A., et al. (1989) Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81, 116-124.
19. 19. Gottesman M. M. and Pastan I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427.
20. 20. Greenberger L. M., Lisanti C. J., Silva J. T. and Horwitz S. B. (1991) Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded by mouse mdr1b. J. Biol. Chem. 266, 20744-20751.
21. 21. Greenberger L. M., Yang C. P., Gindin E. and Horwitz S. B. (1990) Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J. Biol. Chem. 265, 4394-4401.
22. 22. Herman L. W., Sharma V., Kronauge J. F., Barbarics E., Herman L. A. and Piwnica-Worms D. (1995) Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J. Med. Chem. 38, 2955-2963.
23. 23. Howell N., Belli T. A., Zaczkiewics L. T. and Belli J. A. (1984) High level, unstable adriamycin resistance in a Chinese hamster mutant cell line with double minute chromosomes. Cancer Res. 44, 4023-4030.
24. 24. Hyafil F., Vergely C., Du Vignaud P. and Grand-Perret T. (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 53, 4595-4602.
25. 25. Kessel D. and Wilberding C. (1985) Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists. Cancer Res. 45, 1687-1691.
26. -: Carrier free? J. Nucl. Med. 16, 639-641.
27. 27. Lee J.-S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A. T. and Bates S. E. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627-638.
28. 28. Lowry O. H., Rosenbrough W. F., Farr A. L. and Randall R. J. (1951) Protein measurements with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
29. - exchange in Chinese hamster ovary cells. Biochemistry 33, 7239-7249.
30. 30. Metherall J., Li H. and Waugh K. (1996) Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J. Biol. Chem. 271, 2634-2640.
31. 31. Metherall J., Waugh K. and Li H. (1996) Progesterone inhibits cholesterol biosynthesis in cultured cells. J. Biol. Chem. 271, 2627-2633.
32. 32. Moscow J. A. and Cowan K. H. (1988) Multidrug resistance. J. Natl. Cancer Inst. 80, 14-20.
33. 33. Piwnica-Worms D., Chiu M. L., Budding M., Kronauge J. F., Kramer R. A. and Croop J. M. (1993) Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53, 977-984.
34. 34. Piwnica-Worms D., Jacob R., Horres C. R. and Lieberman M. (1983) Transmembrane chloride flux in tissue-cultured chick heart cells. J. Gen. Physiol. 81, 731-748.
35. 35. Piwnica-Worms D., Kronauge J. F. and Chiu M. L. (1990) Uptake and retention of hexakis(2-methoxy isobutyl isonitrile) technetium(I) in cultured chick myocardial cells: Mitochondrial and plasma membrane potential dependence. Circulation 82, 1826-1838.
36. 36. Piwnica-Worms D., Rao V., Kronauge J. and Croop J. (1995) Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34, 12210-12220.
37. 37. Rao V. V., Chiu M. L., Kronauge J. F. and Piwnica-Worms D. (1994) Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-SESTAMIBI. J. Nucl. Med. 35, 510-515.
38. 38. Ritchie R. J. (1984) A critical assessment of the use of lipophilic cations as membrane potential probes. Prog. Biophys. Mol. Biol. 43, 1-32.
39. 39. Saeki T., Ueda K., Tanigawara Y., Hori R. and Komano T. (1993) Human P-glycoprotein transports cyclosporin A and FK506. J. Biol. Chem. 268, 6077-6080.
40. 40. Safa A. R. (1992) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest. 10, 295-305.
41. 41. Sarkadi B., Price E. M., Boucher R. C., Germann U. A. and Scarborough G. A. (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J. Biol. Chem. 267, 4854-4858.
42. 42. Sehested M., Skovsgaard T., van Deurs B. and Winther-Nielsen H. (1987) Increase in non-specific absorptive endocytosis in anthracycline and vinca alkaloid resistant Ehrlich ascites tumor cell lines. J. Natl. Cancer. Inst. 78, 171-179.
43. 2) ethylenediamine-bis[propyl(R-benzylimino)]metal(III) cations. J. Med. Chem. 39, 3483-3490.
44. 44. Sikic B. I. (1993) Modulation of multidrug resistance: At the threshold. Blood 11, 1629-1635.
45. 45. Skovsgaard T. (1989) Drug transport in multidrug-resistant tumor cells: A revision of the pump hypothesis. Coll. INSERM 191, 233-244.
46. 46. Slater L., Sweet P., Stupecky M. and Gupta S. (1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77, 1405-1408.
47. 47. Tamai I. and Safa A. R. (1991) Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J. Biol. Chem. 266, 16796-16800.
48. 48. Tew K. D., Houghton P. J. and Houghton J. A. (1993) Modulation of P-glycoprotein-mediated multidrug resistance. In: Preclinical and Clinical Modulation of Anticancer Drugs, pp. 125-196. CRC Press, Boca Raton, FL.
49. 49. Tsuruo T., Lida H., Kitatani Y., Yokata K., Tsukagoshi S. and Sakurai Y. (1984) Effects of quinidine related compounds on cytotoxicity and cellular accumulation of vincristine and Adriamycin in drug-resistant tumor cells. Cancer Res. 44, 4303-4307.
50. 50. Tsuruo T., Lida H., Tsukagoshi S. and Sakurai Y. (1981) Overcoming vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967-1972.
51. 51. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., Komano T. and Hori R. (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem. 267, 24248-24252.
52. 52. van Helvoort A., Smith A. J., Sprong H., Fritzsche I., Schinkel A. H., Borst P. and van Meer G. (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87, 507-517.
53. 53. Yang C. P., Cohen D., Greenberger L. M., Hsu S. I. and Horwitz S. B. (1990) Differential transport properties of two mdr gene products are distinguished by progesterone. J. Biol. Chem. 265, 10282-10288.
54. 54. Yang C. P., DePinho S. G., Greenberger L. M., Arceci R. J. and Horwitz S. B. (1989) Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J. Biol. Chem. 264, 782-788.
55. 55. Yusa K. and Tsuruo T. (1989) Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006.
56. 56. Zhang L., Sachs C. W., Fu H.-W., Fine R. L. and Casey P. J. (1995) Characterization of prenylcysteines that interact with P-glycoprotein and inhibit drug transport in tumor cells. J. Biol. Chem. 270, 22859-22865.